Open AccessThe updates on Middle East Respiratory Syndrome coronavirus (MERS-CoV) epidemiology, pathogenesis, viral genome and currently available drugs
Author(s) -
Surender Singh Jadav,
Narayana Murthy Ganta,
Anoop Kumar,
Nirnoy Dan,
Neha Padma Mohanty
Publication year - 2016
Publication title -
journal of pahramaceutical chemistry
Language(s) - English
Resource type - Journals
ISSN - 2349-5731
DOI - 10.14805/jphchem.2016.art47
Subject(s) - middle east respiratory syndrome coronavirus , middle east respiratory syndrome , epidemiology , outbreak , disease , medicine , pandemic , virology , coronavirus , vaccination , immunology , covid-19 , infectious disease (medical specialty) , pathology
The Middle East Respiratory Syndrome (MERS) is caused by the novel coronavirus belongs to the family Betacoronaviridae was first identified in Saudi Arabia during 2012. The first epidemic outbreak of the MERS-CoV has been started reporting in the South Korea and other Asian Countries. The disease was transmitted to humans to humans from the Middle East to other countries through travelling history. The MERS-CoV is responsible for the lower acute and severe respiratory disorder causes the shortness of breath along with fever and cough. The treatment for the disease is purely symptomatic and vaccination is not existed. In the present work we are tried to compile the epidemiology, pathogenesis, viral genome and currently available drugs. At the last the promising approaches for the drug design and development process has been presented.